Next-generation targeted cancer therapy

Innovation for Health, February 12th, 2014
SynAffix introduction

- Founded in 2010
- Located in Oss
- Currently 8 fte (of which 6 are PhDs)
- Launch of ADC technology platform in 2012
- Privately held

Peter van de Sande
MSc, MBA, MBL
Chief Executive Officer

Floris van Delft
PhD
Chief Scientific Officer

Sander van Berkel
PhD
Chief Technology Officer

www.synaffix.com
Targeted cancer therapeutics

**ADC: Antibody-Drug Conjugate**

- Selective tumor targeting
- Local release of toxin
- Fewer side effects
- Increased therapeutic window

**The ‘Guided missile’ or ‘Trojan horse’?**

**Fundamental advantages of ADCs:**
- Selective tumor targeting
- Local release of toxin
- Fewer side effects
- Increased therapeutic window
Frontrunners in targeted drug delivery

**ADCETRIS™**
- Treatment for Hodgkin lymphoma or sALCL
- Market introduction 2011 (*FDA fast track*)
- Ongoing trials for >6 other indications

**KADCYLA™**
- Treatment of breast cancer
- Market approval in 2013

Approximately 30 other ADCs currently in clinical trials
Heterogeneity and SynAffix solution

Attenuated Efficacy
Immunogenicity
Complex and lengthy Q&A

SynAffix ADC based on same components
In vivo efficacy

Median tumor volume in mouse xenograft

- Vehicle
- Kadcyla™ (9 mg/kg)
- Trast-vc-may (3 mg/kg)
- Trast-Ahx-may (9 mg/kg)
Therapeutic window

- Applicable across various oncology indications
- Improved clinical benefit
- Efficient partnering model; established collaborations with several big pharma

www.synaffix.com